Seres therapeutics presents microbiome therapeutic research at the 2022 american society of clinical oncology (asco) annual meeting

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (de486) to prevent or treat gastrointestinal (gi) mucositis – a common and often painful complication of radiation and chemotherapy involving the breakdown of the rapidly-dividing epithelial cells lining the gi tract. these results are availabl
MCRB Ratings Summary
MCRB Quant Ranking